Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointment of Ben Palleiko as Senior Advisor and the promotion of Adam Simpson to Executive Partner. The appointments further strengthen FLS’ leadership team and support the firm’s continued efforts to expand its presence across key biotechnology hubs, including the East Coast.

“Ben and Adam each bring exceptional leadership experience and a proven track record of helping build and grow innovative life sciences companies,” said Patrick Heron, Managing Partner at FLS. “We are further strengthening our ability to support entrepreneurs and management teams developing potentially transformative therapies for patients. Ben’s operational and commercial expertise and Adam’s experience founding, scaling, and guiding emerging biotechnology companies will be invaluable as we continue to grow our investment platform.”

Mr. Palleiko joins Frazier Life Sciences with more than 25 years of experience as an executive in the life sciences industry. Most recently, he served as Chief Executive Officer and a member of the Board of Directors of KalVista Pharmaceuticals, where he led the company through its acquisition by Chiesi Group in June 2026. During his tenure, KalVista discovered and developed EKTERLY®, the first oral therapy approved for the treatment of acute hereditary angioedema (HAE) attacks, and executed its successful global commercial launch. Prior to KalVista, Mr. Palleiko served as Senior Vice President and Chief Financial Officer of Ore Pharmaceutical Holdings and Penwest Pharmaceuticals and spent a decade as an investment banker at firms including Robertson Stephens. Earlier in his career, he served as a Naval Aviator in the U.S. Navy. Mr. Palleiko holds a B.A. in Quantitative Economics from Tufts University and an M.B.A. in Finance and an M.A. in International Relations from the University of Chicago.

“I am pleased to join the Frazier Life Sciences team and work alongside a group that has made a meaningful impact across the industry,” said Mr. Palleiko. “I look forward to supporting innovative biotechnology companies as they translate scientific advances into important new therapies for patients.”

Mr. Simpson has been promoted from Venture Partner to Executive Partner at FLS. In his expanded role, he will continue to focus on identifying and developing new company creation opportunities.

Mr. Simpson joined FLS in 2024 and brings extensive operational and emerging company experience, with particular expertise in building leadership teams, advancing innovative technologies through clinical proof of concept, and leading significant financing, partnering and acquisition transactions. Prior to joining FLS, Mr. Simpson served as a co-founder, executive and/or board member of numerous biotechnology companies that have either been acquired or gone public. He holds a B.S. in biochemistry from the University of California, San Diego, and a J.D. from the University of Minnesota Law School.

About Frazier Life Sciences:

Frazier Life Sciences (FLS) invests globally in private and publicly traded companies that discover, develop, and commercialize innovative biopharmaceuticals. The firm manages over $5 billion in capital across venture and public strategies. Since 2010, FLS portfolio companies have achieved 76 FDA-approved therapeutics and completed more than 60 IPOs or strategic acquisitions.

FLS is headquartered in Palo Alto, CA, with offices in San Diego, Seattle and Boston.

For more information about FLS, please visit frazierls.com and follow us on LinkedIn.

Media gallery

About The Author
Business Wire